Sponsored by:
Enter the Era of Modernized mRNA Therapeutics Production
CleanCap® Case study
A leading COVID-19 vaccine manufacturer that uses TriLink’s CleanCap® reagent in their formulation processes needed to rapidly scale-up production and analytical testing capabilities to meet aggressive timelines and help to halt the global pandemic.
TriLink successfully increased CleanCap reagent production by 9x in 6 months via a massive expansion of our ISO-certified manufacturing space. This enabled us to provide substantial amounts of the highest-quality product to vaccine manufacturing facilities in the U.S., Asia, and Europe—accelerating the vaccine’s development for improved health outcomes across the globe.
